Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-OG25, to assess health-related quality of life in patients with cancer of the oesophagus, the oesophago–gastric junction and the stomach

Pernilla Lagergren(Imperial College London), Jane Blazeby(University Hospitals Bristol NHS Foundation Trust), Orhan Sezer(Charité - Universitätsmedizin Berlin), Eva Hammerlid(Sahlgrenska University Hospital), H. J. Stein(LMU Klinikum), Eric Van Cutsem(Universitair Ziekenhuis Leuven), Andrew Bottomley(European Organisation for Research and Treatment of Cancer), Thierry Conroy(Inserm), Richard Hardwick(Addenbrooke's Hospital), Peter Fayers(University of Aberdeen)
European Journal of Cancer
August 17, 2007
10.1016/j.ejca.2007.07.005
Cited by 217

Related Papers

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
|The Lancet|2010|7.3k
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
|New England Journal of Medicine|2018|2.8k
EORTC QLQ-C30 Scoring Manual
|Research at the University of Copenhagen (University of Copenhagen)|1995|2.4k